Vorinostat, also known by its chemical name suberoylanilide hydroxamic acid (SAHA), is a pivotal pharmaceutical compound classified as an antineoplastic agent and a novel histone deacetylase (HDAC) inhibitor. This groundbreaking drug represents a significant advancement in targeted cancer therapy, offering a new approach to combat various malignancies. Its chemical structure is a derivative of benzamide, which plays a key role in its selective inhibitory action against HDAC activity. This inhibition leads to a crucial increase in histone acetylation levels, fundamentally altering gene expression, which is vital for its therapeutic effects.

The core mechanism of Vorinostat lies in its ability to induce tumor cell differentiation and apoptosis—programmed cell death—while simultaneously inhibiting angiogenesis (the formation of new blood vessels that feed tumors) and the proliferation of cancer cells. These multi-faceted actions underscore its comprehensive attack on cancer progression. Vorinostat is well absorbed after oral administration and efficiently distributed to various tissues throughout the body, primarily metabolized by the liver and excreted through urine, ensuring systemic therapeutic reach.

Clinically, Vorinostat is primarily utilized for the treatment of cutaneous T-cell lymphoma (CTCL), especially in patients whose disease has progressed, persisted, or recurred after at least two systemic therapies. Its approval for CTCL highlights its importance in dermatologic oncology. Beyond this primary indication, Vorinostat's therapeutic potential has been extensively explored in various clinical and preclinical investigations. It has shown promising results in combination treatment schemes for other solid tumors, including breast cancer and prostate cancer, where its epigenetic regulation properties can enhance the sensitivity of other anti-cancer drugs. Further research has explored its activity against Sézary syndrome, a type of lymphoma closely related to CTCL, as well as recurrent glioblastoma multiforme, advanced non-small-cell lung carcinoma (NSCLC), and myelodysplastic syndromes. Preclinical studies also suggest its utility as an HIV latency reversing agent, and its potential to address pathophysiological changes in conditions such as alpha-1 antitrypsin deficiency, cystic fibrosis, and even human papillomavirus (HPV) infections, showcasing its broad biological impact and potential future applications.

Vorinostat is typically supplied as a high-purity white powder, with purity commonly exceeding 99%. Its chemical identity is defined by the molecular formula C14H20N2O3, a molecular weight of 264.32, and CAS Registry Number 149647-78-9. Adhering to stringent pharmaceutical standards, including certifications like GMP, HSE, ISO 9001, USP, and BP, ensures its quality, safety, and suitability for pharmaceutical applications. This rigorous quality control is paramount for its use as a crucial active pharmaceutical ingredient.

As a dedicated manufacturer and supplier of premium pharmaceutical raw materials, NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing high-quality Vorinostat powder to meet global demands. We maintain significant production capabilities and a robust supply chain to ensure consistent availability and timely delivery for our partners in research and commercial sectors worldwide. For organizations seeking to buy Vorinostat for their ongoing projects or looking to explore the current Vorinostat price for bulk purchase, we encourage direct inquiry. Our commitment is to facilitate advancements in medicine by supplying a reliable and certified product.